Share on StockTwits

Veracyte (NASDAQ:VCYT) Insider Christopher M. Hall unloaded 3,000 shares of Veracyte stock on the open market in a transaction dated Thursday, June 19th. The shares were sold at an average price of $14.99, for a total transaction of $44,970.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Veracyte (NASDAQ:VCYT) traded up 3.75% on Monday, hitting $16.88. The stock had a trading volume of 96,427 shares. Veracyte has a 52-week low of $10.88 and a 52-week high of $19.00. The stock has a 50-day moving average of $14.15 and a 200-day moving average of $14.87. The company’s market cap is $357.4 million.

Veracyte (NASDAQ:VCYT) last released its earnings data on Thursday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.31) by $0.01. The company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $7.19 million. During the same quarter last year, the company posted ($9.04) earnings per share. Veracyte’s revenue was up 70.5% compared to the same quarter last year. Analysts expect that Veracyte will post $-1.31 EPS for the current fiscal year.

Separately, analysts at Piper Jaffray initiated coverage on shares of Veracyte in a research note on Thursday. They set an “overweight” rating and a $21.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating, Veracyte presently has a consensus rating of “Buy” and an average price target of $20.50.

Veracyte, Inc is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.